Litcius/Paper detail

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis

Marla C. Dubinsky, Lorna Charles, Krzysztof Selmaj, Giancarlo Comi, Anthony Krakovich, Melissa Rosen, C. Janneke van der Woude, Uma Mahadevan

2024Inflammatory Bowel Diseases30 citationsDOIOpen Access PDF

Abstract

Lay Summary This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn’s disease, or multiple sclerosis and in healthy volunteers treated with ozanimod. There was no increased incidence of fetal abnormalities or adverse pregnancy outcomes with ozanimod exposure during early pregnancy.

Topics & Concepts

MedicineUlcerative colitisCrohn's diseaseDiseaseMultiple sclerosisPregnancyInternal medicineCrohn diseaseGastroenterologyInflammatory bowel diseaseDermatologyImmunologyBiologyGeneticsPregnancy and Medication ImpactReproductive System and PregnancyPreterm Birth and Chorioamnionitis
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis | Litcius